rawfin.tv
INmune Bio Stock Holds Steady as UK Regulatory Filing Plans Progress
MarketsstocksAI Generated

INmune Bio Stock Holds Steady as UK Regulatory Filing Plans Progress

By rawfin.tv Markets Desk||Updated |1 min read|AI-assisted · Methodology

INmune Bio's stock closed at $1.93 as the company advances plans for a UK regulatory filing for its drug Ebstrocel (CORDStrom). The filing is anticipated in Q4 2026, marking a key milestone for the biotech firm.

INmune Bio StockBiotechRegulatory FilingDrug DevelopmentUK Market

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks